Novel targets for myeloma bone disease

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 11, 2008, Pages 1377-1387

  Roodman, G David ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bone disease; Myeloma; Novel treatments; Osteoblast; Osteoclast

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; BLOCKING ANTIBODY; BORTEZOMIB; CHEMOKINE RECEPTOR ANTAGONIST; COLONY STIMULATING FACTOR RECEPTOR; DENOSUMAB; DEXAMETHASONE; DICKKOPF HOMOLOG 1; DICKKOPF HOMOLOG 1 ANTIBODY; DOXORUBICIN; FRIZZLED PROTEIN; I KAPPA B KINASE INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 7; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MELPHALAN; MLN 3897; NEUTRALIZING ANTIBODY; NOTCH RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR ANTIBODY; PHOSPHATE; PROTEIN INHIBITOR; SECRETED FRIZZLED RELATED PROTEIN 2; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BONE DISEASE; BONE METASTASIS; BONE NECROSIS; CELL ACTIVITY; CELL STIMULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG TARGETING; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA BONE DISEASE; NEPHROTOXICITY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PYRAZINES; RANK LIGAND;

EID: 56249122936     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.11.1377     Document Type: Review

References (85)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73
2. Melton LJ 3rd, Chrischilles EA, Cooper C, et al. How many women have osteoporosis? J Bone Miner Res 2005;20:886-92
3. Barille-Nion S, Bataille R. New insights in myeloma-induced osteolysis. Leuk Lymphoma 2003;44:1463-7
4. Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-κB ligand (RANKL). Exp Hematol 2004; 32:685-91
5. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004;32:290-2
6. Bataille R, Chappard D, Marcelli C, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989;7:1909-14
7. Bataille R, Chappard D, Marcelli C, et al. Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol 1990;76:484-7
8. Vejlgaard T, Abildgaard N, Jans H, et al. Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens. Eur J Haematol 1997;58:104-8
9. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64
10. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001;98:11581-6
11. Yaccoby S, Pearse RN, Johnson CL, et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-90
12. Vij R, Horvath N, Spencer A, et al. An open label phase II trial of Denosumab in the treatment of relapsed or plateau-phase myeloma. Blood 2007;118:1054A
13. Seidel C, Hjertner O, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001;98:2269-71
14. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98:3534-40
15. Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97:887-92
16. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527-33
17. Sezer O, Heider U, Zavrski I, et al. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094-8
18. Sezer O, Heider U, Jakob C, et al. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 2002;99:4646-7
19. Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 2004;64:2016-23
20. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003;102:1064-9
21. Cook DN. The role of MIP-1α in inflammation and hematopoiesis. J Leukoc Biol 1996;59:61-6
22. Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood 2002;100:2195-202
23. Fuller K, Owens JM, Chambers TJ. Macrophage inflammatory protein-1 alpha and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts. J Immunol 1995;154:6065-72
24. Kukita T, Nomiyama H, Ohmoto Y, et al. Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment. Lab Invest 1997;76:399-406
25. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-5
26. Hashimoto T, Abe M, Oshima T, et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1α and MIP-1β correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 2004;125:38-41
27. Uneda S, Hata H, Matsuno F, et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 2003;120:53-5
28. Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001;108:1833-41
29. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003;102:311-9
30. Oba Y, Lee JW, Ehrlich LA, et al. MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 2005;33:272-8
31. Vallet S, Raje N, Ishitsuka K, et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007;110:3744-52
32. Menu E, De Leenheer E, De Raeve H, et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 2006;23:291-300
33. Lee JW, Chung HY, Ehrlich LA, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004;103:2308-15
34. Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 2002;16:1182-8
35. de la Mata J, Uy HL, Guise TA, et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995;95:2846-52
36. Teoh G, Anderson KG. Interaction of tumor and hosT cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 1997;11:27-42
37. Yasui H, Hideshima T, Richardson PG, et al. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol 2006;132:385-97
38. Jundt F, Probsting KS, Anagnostopoulos I, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004;103:3511-5
39. Nefedova Y, Sullivan DM, Bolick SC, et al. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008;111:2220-9
40. Schwatzer R, Kaiser M, Acikgoez O, et al. Notch inhibition blocks multiple myeloma cell-induced osteoclast activation. Leukemia 2008. Published online 2008 June 5, doi:10.1038/leu.2008.138
41. Roodman GD. Regulation of osteoclast differentiation. Ann NY Acad Sci 2006;1068:100-9
42. Kurihara N, Hiruma Y, Zhou H, et al. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest 2007;117:133-42
43. Hiruma Y, Honjo T, Jelinek D, et al. Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood 2008
44. Anderson KC, Shaughnessy JD Jr, Barlogie B, et al. Multiple myeloma. Hematology Am Soc Hematol Educ Program 2002:214-40
45. Hjorth-Hansen H, Seifert MF, Borset M, et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 1999;14:256-63
46. Silvestris F, Cafforio P, Calvani N, et al. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 2004;126:475-86
47. Evans CE, Galasko CS, Ward C. Does myeloma secrete an osteoblast inhibiting factor? J Bone Joint Surg Br 1989;71:288-90
48. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004;341:19-39
49. Bain G, Muller T, Wang X, et al. Activated β-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem Biophys Res Commun 2003;301:84-91
50. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94
51. Qiang YW, Chen Y, Stephens O, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008;112:196-207
52. Politou MC, Heath DJ, Rahemtulla A, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006;119:1728-31
53. Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008;80:490-4
54. Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005;106:2472-83
55. Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007;109(5):2106-11
56. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress osteoblast differentiation by secreting a soluble Wnt inhibitor, sFRP-2 [abstract 2356]. American Society of Hematology, San Diego, CA; 2004
57. De Vos J, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001;98:771-80
58. Giuliani N, Morandi F, Tagliaferri S, et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007;67:7665-74
59. Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003;102:4504-11
60. Ehrlich LA, Chung HY, Ghobrial I, et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005;106:1407-14
61. Weitzmann MN, Roggia C, Toraldo G, et al. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002;110:1643-50
62. Giuliani N, Rizzoli V. Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leuk Lymphoma 2007;48:2323-9
63. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-93
64. Berenson JR. Bone disease in myeloma. Curr Treat Options Oncol 2001;2:271-83
65. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8
66. Kropff M, Bisping G, Wenning D, et al. Proteasome inhibition in multiple myeloma. Eur J Cancer 2006;42:1623-39
67. Garrett IR, Chen D, Gutierrez G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003;111:1771-82
68. Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005;131:71-3
69. Buzaid AC, Durie BG. Management of refractory myeloma: a review. J Clin Oncol 1988;6:889-905
70. Kim HJ, Zhao H, Kitaura H, et al. Glucocorticoids and the osteoclast. Ann NY Acad Sci 2007;1116:335-9
71. Heider U, Kaiser M, Muller C, et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006;77:233-8
72. Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006;135:688-92
73. Terpos E, Sezer O, Croucher P, et al. Myeloma bone disease and proteasome inhibition therapies. Blood 2007;110:1098-104
74. Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007;110:334-8
75. Oyajobi BO, Garrett IR, Gupta A, et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol 2007;139:434-8
76. Yaccoby S, Wezeman MJ, Zangari M, et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 2006;91:192-9
77. Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood 2008;112:159-68
78. Qiang YW, Shaughnessy JD Jr, Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 2008;112:374-82
79. Edwards CM, Edwards JR, Lwin ST, et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008;111:2833-42
80. von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007;21:2025-34
81. Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 2006;42:1612-22
82. Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006;107:3098-105
83. Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008
84. Onyia JE, Libermann TA, Bidwell J, et al. Parathyroid hormone (1-34)-mediated interleukin-6 induction. J Cell Biochem 1997;67:265-74
85. Mukherjee S, Raje N, Schoonmaker JA, et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008;118:491-504